EDIT Editas Medicine Inc

Price (delayed)

$3.75

Market cap

$309.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.34

Enterprise value

$283.54M

As a leading genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas9 and CRISPR/Cas12a (also known as Cpf1) genome editing systems into a ...

Highlights

EDIT's EPS is up by 21% year-on-year but it is down by 13% since the previous quarter

Editas Medicine's net income has decreased by 16% QoQ but it has increased by 6% YoY

Editas Medicine's quick ratio has shrunk by 53% YoY and by 16% QoQ

EDIT's equity is down by 42% year-on-year and by 21% since the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://www.editasmedicine.com

Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of EDIT

Market

Shares outstanding

82.48M

Market cap

$309.29M

Enterprise value

$283.54M

Valuations

Price to earnings (P/E)

N/A

Price to book (P/B)

1.33

Price to sales (P/S)

4.6

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

4.23

Earnings

Revenue

$67.03M

EBIT

-$213.03M

EBITDA

-$207.22M

Free cash flow

-$171.54M

Per share

EPS

-$2.34

Free cash flow per share

-$2.08

Book value per share

$2.82

Revenue per share

$0.81

TBVPS

$4.68

Balance sheet

Total assets

$384.8M

Total liabilities

$152.79M

Debt

$38.7M

Equity

$232.01M

Working capital

$212.05M

Liquidity

Debt to equity

0.17

Current ratio

3.85

Quick ratio

3.76

Net debt/EBITDA

0.12

Margins

EBITDA margin

-309.1%

Gross margin

100%

Net margin

-288.6%

Operating margin

-317.8%

Efficiency

Return on assets

-42.3%

Return on equity

-62.6%

Return on invested capital

-62.2%

Return on capital employed

-68.6%

Return on sales

-317.8%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

EDIT stock price

How has the Editas Medicine stock price performed over time

Intraday

-0.79%

1 week

7.45%

1 month

-4.34%

1 year

-58.33%

YTD

-62.98%

QTD

-19.7%

Financial performance

How have Editas Medicine's revenue and profit performed over time

Revenue

$67.03M

Gross profit

$67.03M

Operating income

-$213.02M

Net income

-$193.45M

Gross margin

100%

Net margin

-288.6%

The net margin has soared by 73% YoY but it has contracted by 21% from the previous quarter

EDIT's operating margin has surged by 72% year-on-year but it is down by 19% since the previous quarter

Editas Medicine's net income has decreased by 16% QoQ but it has increased by 6% YoY

EDIT's operating income is down by 15% since the previous quarter

Growth

What is Editas Medicine's growth rate over time

Valuation

What is Editas Medicine stock price valuation

P/E

N/A

P/B

1.33

P/S

4.6

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

4.23

EDIT's EPS is up by 21% year-on-year but it is down by 13% since the previous quarter

EDIT's P/B is 63% below its 5-year quarterly average of 3.6 and 33% below its last 4 quarters average of 2.0

EDIT's equity is down by 42% year-on-year and by 21% since the previous quarter

The P/S is 89% less than the 5-year quarterly average of 40.7 and 63% less than the last 4 quarters average of 12.6

The revenue has declined by 3.4% since the previous quarter

Efficiency

How efficient is Editas Medicine business performance

EDIT's return on sales has surged by 72% year-on-year but it is down by 19% since the previous quarter

The ROE has decreased by 32% from the previous quarter and by 14% YoY

Editas Medicine's ROA has decreased by 26% from the previous quarter and by 5% YoY

EDIT's return on invested capital is down by 17% since the previous quarter but it is up by 9% year-on-year

Dividends

What is EDIT's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EDIT.

Financial health

How did Editas Medicine financials performed over time

EDIT's total assets is 152% higher than its total liabilities

Editas Medicine's quick ratio has shrunk by 53% YoY and by 16% QoQ

The current ratio has plunged by 52% YoY and by 16% from the previous quarter

The debt is 83% less than the equity

The company's debt to equity has surged by 89% YoY and by 42% QoQ

EDIT's equity is down by 42% year-on-year and by 21% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.